Vascular mechanisms in osteoarthritis

Ghosh, Peter; Cheras, Phillip A

doi:10.1053/berh.2001.0188

Cited by 81 publications

(65 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, based on the existing literature, 11,13,14,19,27 we can only speculate as to whether the longterm clinical outcomes would be superior to the current practice of spinal fusion. In particular, the biomechanical characteristics of a cartilaginous tissue as a replacement for the tougher fibrocartilaginous anulus fibrosis must be questioned in relation to maintaining the functional stability of the cervical spine during articulation and axial loading.…”

Section: Discussionmentioning

confidence: 99%

“…12,18 Extensive in vitro and animal model studies have shown that PPS is antiinflammatory, promotes fibrinolysis, and stimulates cartilage matrix synthesis by chondrocytes. 12,13,15 Pentosan polysulfate is also a potent inhibitor of serine proteinases, and it downregulates collagenase production by chondrocytes at the gene promotor level. 1,12 More recently, PPS has been shown to inhibit the cartilage aggrecanases ADAMTS4 and ADAMTS5 35,36 and their binding to the endogenous inhibitor TIMP-3.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Cervical motion preservation using mesenchymal progenitor cells and pentosan polysulfate, a novel chondrogenic agent: preliminary study in an ovine model

Goldschlager

Ghosh

Zannettino

et al. 2010

FOC

Self Cite

View full text Add to dashboard Cite

Object There is an unmet need for a procedure that could generate a biological disc substitute while at the same time preserving the normal surgical practice of achieving anterior cervical decompression. The objective of the present study was to test the hypothesis that adult allogeneic mesenchymal progenitor cells (MPCs) formulated with a chondrogenic agent could synthesize a cartilaginous matrix when implanted into a biodegradable carrier and cage, and over time, might serve as a dynamic interbody spacer following anterior cervical discectomy (ACD). Methods Eighteen ewes were divided randomly into 3 groups of 6 animals. Each animal was subjected to C3–4 and C4–5 ACD followed by implantation of bioresorbable interbody cages and graft containment plates. The cage was packed with 1 of 3 implants. In Group A, the implant was Gelfoam sponge only. In Group B, the implant consisted of Gelfoam sponge with 1 million MPCs only. In Group C, the implant was Gelfoam sponge with 1 million MPCs formulated with the chondrogenic agent pentosan polysulfate (PPS). In each animal the cartilaginous endplates were retained intact at 1 level, and perforated in a standardized manner at the other level. Allogeneic ovine MPCs were derived from a single batch of immunoselected and culture-expanded MPCs isolated from bone marrow of outbred sheep (mixed stock). Radiological and histological measures were used to assess cartilage formation and the presence or absence of new bone formation. Results The MPCs with or without PPS were safe and well-tolerated in the ovine cervical spine. There was no significant difference between groups in the radiographic or histological outcome measures, regardless of whether endplates were perforated or retained intact. According to CT scans obtained at 3 months after the operation, new bone formation within the interbody space was observed in the Gelfoam only group (Group A) in 9 (75%) of 12 interbody spaces, and 11 (92%) of 12 animals in the MPC cohort (Group B) had new bone formation within the interbody space. Significantly, in the MPC & PPS group (Group C), there were only 1 (8%) of 12 levels with new bone formation (p = 0.0009 vs Group A; p = 0.0001 vs Group B). According to histological results, there was significantly more cartilaginous tissue within the interbody cages of Group C (MPC & PPS) compared with both the control group (Group A; p = 0.003) and the MPC Group (p = 0.017). Conclusions This study demonstrated the feasibility of using MPCs in combination with PPS to produce cartilaginous tissue to replace the intervertebral disc following ACD. This biological approach may offer a means preserving spinal motion and offers an alternative to fusion to artificial prostheses.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Cervical motion preservation using mesenchymal progenitor cells and pentosan polysulfate, a novel chondrogenic agent: preliminary study in an ovine model

Goldschlager

Ghosh

Zannettino

et al. 2010

FOC

Self Cite

View full text Add to dashboard Cite

show abstract

“…Based on their vascular and antiinflammatory effects, together with evidence from animal studies (4), statins have been proposed as potential therapies for the treatment and/or prevention of osteoarthritis (OA) (5)(6)(7). A number of studies have examined associations between statin use and OA.…”

Section: Introductionmentioning

confidence: 99%

Is Statin Use Associated With New Joint‐Related Symptoms, Physical Function, and Quality of Life? Results From Two Population‐Based Cohorts of Women

Peeters

Tett

Conaghan

et al. 2014

Arthritis Care & Research

View full text Add to dashboard Cite

show abstract

“…Ból kolana jest najbardziej stałym i najdokuczliwiej odbieranym przez chorych objawem zmian patologicznych, choć pojawia się stosunkowo późno, zwykle w zaawansowanych stadiach choroby. Dolegliwościom bólowym towarzyszy problem ograniczenia ruchomości stawu kolanowego [1,2,3]. W patogenezie choroby zwyrodnieniowej od dawna podkreśla się rolę stresu oksydacyjnego, podając kilka przypuszczalnych mechanizmów miejscowego powstawania reaktywnych form tlenu (RFT) [4,5,6,7].…”

Section: W St ę Punclassified

Viscosupplementation for the treatment of osteoarthritis of the knee

Ostałowska¹,

Skowron²,

Birkner³

et al. 2017

Ann. Acad. Med. Siles.

View full text Add to dashboard Cite

W S T Ę P:Choroba zwyrodnieniowa stawów kolanowych (gonartroza -GA) należy do najczęstszych schorzeń narządu ruchu, a ból i ograniczenie ruchomości kolana są najdotkliwiej odbieranymi przez pacjentów objawami zmian zwyrodnieniowych. Celem pracy było sprawdzenie, czy podanie dostawowe preparatu kwasu hialuronowego wpływa na funkcje stawu kolanowego, wybrane parametry układu antyoksydacyjnego i natężenie stresu oksydacyjnego we krwi u pacjentów z gonartrozą. M A T E R I A Ł I M E T O D Y:Grupa badana 1K obejmowała 96 pacjentów z chorobą zwyrodnieniową stawu kolanowego, którym podano kwas hialuronowy do jednego stawu kolanowego, natomiast do grupy badanej 2K włączono 33 pacjentów, którym podano kwas hialuronowy do obu stawów kolanowych. Badanie prowadzono przez 40 tygodni według ustalonego protokołu. Oznaczono całkowity status oksydacyjny (TOS) osocza, zawartość grup sulfhydrylowych (SH) w surowicy, aktywność katalazy (CAT) w erytrocytach, aktywność dysmutazy ponadtlenkowej (SOD) w osoczu i erytrocytach, aktywność peroksydazy glutationowej (GPx) w erytrocytach. W Y N I K I: Po leczeniu wiskosuplementacyjnym odnotowano zmniejszenie nasilenia bólu oraz poprawę w badanych skalach VAS i HHS, przy czym nieco większą poprawę stwierdzono w przypadku zajęcia jednego kolana. Po leczeniu dostawowym kwasem hialuronowym stwierdzono znamienny spadek aktywności SOD oraz CAT a wzrost aktywności GPx, wzrost stężenia grup SH w obu grupach oraz spadek stężenia TOS. WNIOSKI: Wiskosuplementacja w chorobie zwyrodnieniowej stawu kolanowego istotnie redukuje ból kolana i poprawia jego funkcje oraz wywołuje korzystne zmiany w układzie antyoksydacyjnym krwi. Efekt leczenia jest porównywalny zarówno w przypadku podawania preparatu kwasu hialuronowego do jednego, jaki i do obu stawów kolanowych. S Ł O W A K L U C Z O W Echoroba zwyrodnieniowa stawu kolanowego, kwas hialuronowy, reaktywne formy tlenu, enzymy antyoksydacyjne

show abstract

Vascular mechanisms in osteoarthritis

Cited by 81 publications

References 39 publications

Cervical motion preservation using mesenchymal progenitor cells and pentosan polysulfate, a novel chondrogenic agent: preliminary study in an ovine model

Cervical motion preservation using mesenchymal progenitor cells and pentosan polysulfate, a novel chondrogenic agent: preliminary study in an ovine model

Is Statin Use Associated With New Joint‐Related Symptoms, Physical Function, and Quality of Life? Results From Two Population‐Based Cohorts of Women

Viscosupplementation for the treatment of osteoarthritis of the knee

Contact Info

Product

Resources

About